Recon: Germany’s Merck in talks to acquire SpringWorks; Judge orders FDA, CDC to restore deleted portions websites
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Trump administration ordered to restore removed CDC and FDA websites (Reuters)
- Halt on Trump administration’s cuts to NIH research payments expanded nationwide (STAT)
- Key GOP senators push back against NIH funding cuts (STAT)
- How RFK Jr. could revive a dormant task force to scrutinize vaccine safety (STAT)
- CVS Health's turnaround efforts in focus amid record-high medical costs (Reuters)
- Insurer Humana forecasts 2025 profit below estimates, expects drop in membership (Reuters)
- FDA Appears to Be Granting Zombie Rare Pediatric Disease Designations Waiting for the Rare Pediatric Disease Priority Review Voucher Program to be Revived (FDA Law Blog)
- Germany's Merck in advanced talks to acquire US biotech firm SpringWorks (Reuters)
- Number of confirmed Ebola cases in Uganda rises to nine (Reuters)
- Updated EU Guidance Reinforces How Notified Bodies Should Use Existing Evidence (MedTech Insight)
- Balancing Competitiveness and Sustainability In EU Regulations, What’s Next For Pharma (Pink Sheet)
- Depemokimab & Tzield Among 10 New EU Filings (Pink Sheet)
- How the ‘amyloid mafia’ took over Alzheimer’s research (STAT)
- Vertex pain pill dominates earnings call discussion (STAT)
- Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos (Endpoints)
- Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout (Endpoints)
- IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic (Endpoints)
- Pfizer’s prostate cancer data leak shows promising results in early-stage study (Endpoints)
- Vertex operations chief Stuart Arbuckle to retire (Endpoints)
- Eli Lilly inks $630M deal for Phase 1 MASH candidate (Endpoints)
- Bayer brings heart health message to Super Bowl, warning millennials to open their eyes to risks (Fierce Pharma)
- Pfizer wins 2025 Super Bowl with ad's 'likeability,' while Hims & Hers' spot takes engagement crown: analysts (Fierce Pharma)
- Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss (BioSpace)
- Former FDA head Gottlieb calls for less regulation of certain AI tools (MedTech Dive)
- Meta Rally Makes History as It Goes on Offensive With AI (Bloomberg)
- Navigating the Unknown: EU HTA Regulation’s Impact on Commercial Confidentiality (Pink Sheet)
- Vance Warns U.S. Allies to Keep AI Regulation Light (The Wall Street Journal)
- Mass General Brigham announces largest layoff in its history amid ongoing restructuring (STAT)
- A check-in on health insurers’ medical costs, and more babies are being born (STAT)
- Stopgap measures against H5N1 bird flu can only go so far (STAT)
- Trump’s tariff impact likely ‘minimal’ for brand-name drugmakers, manufacturing partners (Endpoints)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
